We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities.
- Authors
Lacouture ME; Anadkat MJ; Bensadoun RJ; Bryce J; Chan A; Epstein JB; Eaby-Sandy B; Murphy BA; MASCC Skin Toxicity Study Group; Lacouture, Mario E; Anadkat, Milan J; Bensadoun, René-Jean; Bryce, Jane; Chan, Alexandre; Epstein, Joel B; Eaby-Sandy, Beth; Murphy, Barbara A
- Abstract
<bold>Background: </bold>Epidermal growth factor receptor inhibitors (EGFRI) produce various dermatologic side effects in the majority of patients, and guidelines are crucial for the prevention and treatment of these untoward events. The purpose of this panel was to develop evidence-based recommendations for EGFRI-associated dermatologic toxicities.<bold>Methods: </bold>A multinational, interdisciplinary panel of experts in supportive care in cancer reviewed pertinent studies using established criteria in order to develop first-generation recommendations for EGFRI-associated dermatologic toxicities.<bold>Results: </bold>Prophylactic and reactive recommendations for papulopustular (acneiform) rash, hair changes, radiation dermatitis, pruritus, mucositis, xerosis/fissures, and paronychia are presented, as well as general dermatologic recommendations when possible.<bold>Conclusion: </bold>Prevention and management of EGFRI-related dermatologic toxicities is critical to maintain patients' health-related quality of life and dose intensity of antineoplastic regimens. More rigorous investigation of these toxicities is warranted to improve preventive and treatment strategies.
- Publication
Supportive Care in Cancer, 2011, Vol 19, Issue 8, p1079
- ISSN
0941-4355
- Publication type
journal article
- DOI
10.1007/s00520-011-1197-6